These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 21457934)

  • 1. Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
    Hoermann G; Cerny-Reiterer S; Perné A; Klauser M; Hoetzenecker K; Klein K; Müllauer L; Gröger M; Nijman SM; Klepetko W; Valent P; Mayerhofer M
    Am J Pathol; 2011 May; 178(5):2344-56. PubMed ID: 21457934
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
    Baumgartner C; Cerny-Reiterer S; Sonneck K; Mayerhofer M; Gleixner KV; Fritz R; Kerenyi M; Boudot C; Gouilleux F; Kornfeld JW; Sillaber C; Moriggl R; Valent P
    Am J Pathol; 2009 Dec; 175(6):2416-29. PubMed ID: 19893034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
    Greiner G; Witzeneder N; Berger A; Schmetterer K; Eisenwort G; Schiefer AI; Roos S; Popow-Kraupp T; Müllauer L; Zuber J; Sexl V; Kenner L; Sperr WR; Valent P; Mayerhofer M; Hoermann G
    Blood; 2017 Jan; 129(3):371-382. PubMed ID: 27856463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ; Gleixner KV; Mirkina I; Cerny-Reiterer S; Peter B; Ferenc V; Kneidinger M; Baumgartner C; Mayerhofer M; Gruze A; Pickl WF; Sillaber C; Valent P
    Blood; 2009 Dec; 114(26):5342-51. PubMed ID: 19850739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.
    Wilson TM; Maric I; Simakova O; Bai Y; Chan EC; Olivares N; Carter M; Maric D; Robyn J; Metcalfe DD
    Haematologica; 2011 Mar; 96(3):459-63. PubMed ID: 21134978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.
    Bandara G; Falduto GH; Luker A; Bai Y; Pfeiffer A; Lack J; Metcalfe DD; Olivera A
    Front Immunol; 2023; 14():1078958. PubMed ID: 37025992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V.
    Gleixner KV; Peter B; Blatt K; Suppan V; Reiter A; Radia D; Hadzijusufovic E; Valent P
    Haematologica; 2013 Sep; 98(9):1450-7. PubMed ID: 23539538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-cell analysis reveals the KIT D816V mutation in haematopoietic stem and progenitor cells in systemic mastocytosis.
    Grootens J; Ungerstedt JS; Ekoff M; Rönnberg E; Klimkowska M; Amini RM; Arock M; Söderlund S; Mattsson M; Nilsson G; Dahlin JS
    EBioMedicine; 2019 May; 43():150-158. PubMed ID: 30975542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV; Mayerhofer M; Cerny-Reiterer S; Hörmann G; Rix U; Bennett KL; Hadzijusufovic E; Meyer RA; Pickl WF; Gotlib J; Horny HP; Reiter A; Mitterbauer-Hohendanner G; Superti-Furga G; Valent P
    Blood; 2011 Aug; 118(7):1885-98. PubMed ID: 21680801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KIT GNNK splice variants: expression in systemic mastocytosis and influence on the activating potential of the D816V mutation in mast cells.
    Chan EC; Bai Y; Bandara G; Simakova O; Brittain E; Scott L; Dyer KD; Klion AD; Maric I; Gilfillan AM; Metcalfe DD; Wilson TM
    Exp Hematol; 2013 Oct; 41(10):870-881.e2. PubMed ID: 23743299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.
    Mayerhofer M; Gleixner KV; Hoelbl A; Florian S; Hoermann G; Aichberger KJ; Bilban M; Esterbauer H; Krauth MT; Sperr WR; Longley JB; Kralovics R; Moriggl R; Zappulla J; Liblau RS; Schwarzinger I; Sexl V; Sillaber C; Valent P
    J Immunol; 2008 Apr; 180(8):5466-76. PubMed ID: 18390729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
    Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibition upregulates Bim and induces caspase-3-dependent apoptosis in human mast cells expressing the Kit D816V mutation.
    Westerberg CM; Hägglund H; Nilsson G
    Cell Death Dis; 2012 Nov; 3(11):e417. PubMed ID: 23152053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications.
    Jara-Acevedo M; Teodosio C; Sanchez-Muñoz L; Álvarez-Twose I; Mayado A; Caldas C; Matito A; Morgado JM; Muñoz-González JI; Escribano L; Garcia-Montero AC; Orfao A
    Mod Pathol; 2015 Aug; 28(8):1138-49. PubMed ID: 26067933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis.
    Lyberg K; Ali HA; Grootens J; Kjellander M; Tirfing M; Arock M; Hägglund H; Nilsson G; Ungerstedt J
    Oncotarget; 2017 Feb; 8(6):9647-9659. PubMed ID: 28038453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.
    Sotlar K; Cerny-Reiterer S; Petat-Dutter K; Hessel H; Berezowska S; Müllauer L; Valent P; Horny HP
    Mod Pathol; 2011 Apr; 24(4):585-95. PubMed ID: 21186345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.